Randomized Phase II Trial of Chemoembolization and Sorafenib

Summary

The study will be a single-center, randomized Phase II study of conventional TACE in combination with sorafenib, given either continuously or sequentially, in patients with unresectable HCC. The primary variables will be tumor response (by MR Imaging) and plasma VEGF levels, prior to and after cTACE.

Timeline

Start

2016-06

Primary completion

2020-06

Completion

2020-06

Outcome

Outcome not reported

Stopped: “A future study will be taking place using the same patient population.”

Drugs

Indications